Quoin Wins EMA Orphan Drug Designation for QRX003
Quoin Pharmaceuticals received EMA orphan drug designation for QRX003 to treat Peeling Skin Syndrome. The company expects to start its first formal clinical trial for the condition before year-end.
Quoin Pharmaceuticals received EMA orphan drug designation for QRX003 to treat Peeling Skin Syndrome. The company expects to start its first formal clinical trial for the condition before year-end.